Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
ALPHACAINE vs LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Blocks voltage-gated sodium channels, inhibiting action potential propagation in neurons and cardiac myocytes.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
1-1.5 mg/kg IV bolus, then 0.5-0.75 mg/kg IV bolus every 5-10 min to a max of 3 mg/kg total loading dose; maintenance infusion 1-4 mg/min IV. For epidural: 5-10 mL of 1-2% solution.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life: 1.5–2 hours (single dose); prolonged to 2–3 hours with repeated dosing or in heart failure, liver disease, or elderly. Context: Effective for 1–2 hours after IV bolus, requiring infusion for sustained effect.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal excretion of unchanged drug and metabolites: ~90% as metabolites (e.g., monoethylglycinexylidide, glycinexylidide), <10% unchanged. Biliary/fecal: minimal (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)